Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
Public ClinicalTrials.gov record NCT06577090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or Obese
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.
Study identification
- NCT ID
- NCT06577090
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 136 participants
Conditions and interventions
Conditions
Interventions
- Nimacimab injection Biological
- Nimacimab placebo injection Biological
- semaglutide injection Combination Product
- Nimacimab 300 mg injection Biological
Biological · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 21, 2024
- Primary completion
- Nov 19, 2026
- Completion
- Feb 27, 2027
- Last update posted
- Jan 13, 2026
2024 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Research Group | Anniston | Alabama | 36207 | — |
| Diablo Clinical Research, Inc. | Walnut Creek | California | 94598 | — |
| Chase Medical Research, LLC | Waterbury | Connecticut | 06708 | — |
| ACCEL Research Sites | Atlanta | Georgia | 30342 | — |
| Center for Advanced Research & Education | Gainesville | Georgia | 30501 | — |
| L-MARC Research Center | Louisville | Kentucky | 40213 | — |
| Be Well Clinical Studies | Lincoln | Nebraska | 68516 | — |
| Palm Research Center | Las Vegas | Nevada | 89148 | — |
| ActivMed Practices & Research | Portsmouth | New Hampshire | 03801 | — |
| Weill Cornell Medicine | New York | New York | 11375 | — |
| Accellacare of Wilmington | Wilmington | North Carolina | 28401 | — |
| Lillestol Research, LLC | Fargo | North Dakota | 58104 | — |
| Velocity Clinical Research, Dallas | Dallas | Texas | 75230 | — |
| Be Well Clinical Studies | Round Rock | Texas | 78681 | — |
| Charlottesville Medical Research | Charlottesville | Virginia | 22911 | — |
| Rainier Clinical Research Center | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06577090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06577090 live on ClinicalTrials.gov.